Enhancing regulatory T cells to improve treatment for myocarditis

Regulatory T cell augmentation by a long noncoding RNA: mechanisms and therapeutic applications in myocarditis

NIH-funded research Cedars-Sinai Medical Center · NIH-10993144

This study is looking at how a specific type of RNA can help boost special immune cells that reduce inflammation and help heal the heart in people with myocarditis, a heart condition often caused by viruses, with the hope of finding better treatments for patients.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionCedars-Sinai Medical Center NIH-funded
Lab location1 site (Los Angeles, United States)
Project IDNIH-10993144 on NIH RePORTER

What this research studies

This research investigates how a long noncoding RNA can enhance regulatory T cells, which play a crucial role in reducing inflammation and promoting healing in myocarditis, an inflammatory heart condition often triggered by viral infections. The approach focuses on understanding the mechanisms behind this enhancement and exploring its therapeutic applications. By potentially allowing for quicker and more effective treatments, this research aims to address the current lack of validated therapies for acute myocarditis. Patients may benefit from improved outcomes through enhanced immune responses that favor heart tissue repair.

Who could benefit from this research

Good fit: Ideal candidates for this research are individuals diagnosed with acute myocarditis, particularly those experiencing severe inflammation and related heart complications.

Not a fit: Patients with chronic heart conditions unrelated to myocarditis or those who do not have an active inflammatory response may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to a novel treatment that significantly improves recovery and reduces complications for patients with myocarditis.

How similar studies have performed: Early phase clinical trials have shown promise in using autologous Treg cell infusion for various conditions, suggesting that similar approaches may be effective for myocarditis.

Where this research is happening

Los Angeles, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Brittle Diabetes Mellitus
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.